Calamos Advisors LLC Bristol Myers Squibb CO Transaction History

Calamos Advisors LLC

$15.7 Billion
Q2 2024

A detailed history of Calamos Advisors LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Calamos Advisors LLC holds 642,306 shares of BMY stock, worth $34.2 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares

642,306

Previous 660,662 2.78%

Holding current value

$34.2 Million

Previous $35.8 Million 25.55%

% of portfolio

0.17%

Previous 0.25%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 25, 2024	SELL	$40.25 - $52.99 $738,829 - $972,684	-18,356 Reduced 2.78%	642,306 $26.7 Million
Q1 2024 May 08, 2024	SELL	$47.98 - $54.4 $628,873 - $713,020	-13,107 Reduced 1.95%	660,662 $35.8 Million
Q4 2023 Jan 31, 2024	SELL	$48.48 - $57.85 $307,023 - $366,364	-6,333 Reduced 0.93%	673,769 $34.6 Million
Q3 2023 Oct 25, 2023	SELL	$57.89 - $64.73 $87,471 - $97,807	-1,511 Reduced 0.22%	680,102 $39.5 Million
Q2 2023 Jul 28, 2023	SELL	$63.71 - $70.74 $15.6 Million - $17.3 Million	-244,526 Reduced 26.4%	681,613 $43.6 Million
Q1 2023 May 03, 2023	SELL	$65.71 - $74.53 $6.63 Million - $7.52 Million	-100,851 Reduced 9.82%	926,139 $64.2 Million
Q4 2022 Jan 25, 2023	SELL	$68.48 - $81.09 $14.4 Million - $17.1 Million	-210,455 Reduced 17.01%	1,026,990 $0
Q3 2022 Oct 24, 2022	SELL	$0.13 - $76.84 $188 - $111,648	-1,453 Reduced 0.12%	1,237,445 $88 Million
Q2 2022 Aug 01, 2022	BUY	$72.62 - $79.98 $8.06 Million - $8.87 Million	110,934 Added 9.83%	1,238,898 $95.4 Million
Q1 2022 May 03, 2022	BUY	$61.48 - $73.72 $9.09 Million - $10.9 Million	147,888 Added 15.09%	1,127,964 $82.4 Million
Q4 2021 Feb 01, 2022	BUY	$53.63 - $62.52 $2.13 Million - $2.48 Million	39,711 Added 4.22%	980,076 $61.1 Million
Q3 2021 Oct 26, 2021	BUY	$59.17 - $69.31 $8.52 Million - $9.98 Million	143,994 Added 18.08%	940,365 $55.6 Million
Q2 2021 Jul 22, 2021	BUY	$61.91 - $67.42 $7.07 Million - $7.7 Million	114,232 Added 16.75%	796,371 $53.2 Million
Q1 2021 Apr 12, 2021	BUY	$59.34 - $66.74 $667,218 - $750,424	11,244 Added 1.68%	682,139 $43.1 Million
Q4 2020 Jan 27, 2021	SELL	$57.74 - $65.43 $1.1 Million - $1.24 Million	-18,983 Reduced 2.75%	670,895 $41.6 Million
Q3 2020 Oct 26, 2020	SELL	$57.43 - $63.64 $2.6 Million - $2.89 Million	-45,338 Reduced 6.17%	689,878 $41.6 Million
Q2 2020 Jul 27, 2020	BUY	$54.82 - $64.09 $5.1 Million - $5.96 Million	93,068 Added 14.49%	735,216 $43.2 Million
Q1 2020 Apr 28, 2020	SELL	$46.4 - $67.43 $1.48 Million - $2.15 Million	-31,818 Reduced 4.72%	642,148 $35.8 Million
Q4 2019 Jan 15, 2020	BUY	$49.21 - $64.19 $12.3 Million - $16 Million	249,074 Added 58.62%	673,966 $43.3 Million
Q3 2019 Oct 21, 2019	BUY	$42.77 - $50.71 $1.15 Million - $1.36 Million	26,910 Added 6.76%	424,892 $21.5 Million
Q2 2019 Aug 07, 2019	BUY	$44.62 - $49.34 $565,290 - $625,088	12,669 Added 3.29%	397,982 $18 Million
Q1 2019 Apr 12, 2019	BUY	$45.12 - $53.8 $109,190 - $130,196	2,420 Added 0.63%	385,313 $18.4 Million
Q4 2018 Jan 24, 2019	BUY	$48.76 - $63.23 $1.67 Million - $2.16 Million	34,234 Added 9.82%	382,893 $19.9 Million
Q3 2018 Oct 22, 2018	BUY	$55.19 - $62.25 $1.43 Million - $1.62 Million	25,996 Added 8.06%	348,659 $21.6 Million
Q2 2018 Jul 17, 2018	SELL	$50.53 - $62.98 $28.6 Million - $35.6 Million	-565,706 Reduced 63.68%	322,663 $17.9 Million
Q1 2018 Apr 13, 2018	SELL	$59.92 - $68.98 $981,249 - $1.13 Million	-16,376 Reduced 1.81%	888,369 $56.2 Million
Q4 2017 Feb 13, 2018	BUY	$59.94 - $65.35 $24.2 Million - $26.4 Million	403,665 Added 80.56%	904,745 $55.4 Million
Q3 2017 Oct 25, 2017	BUY	$55.23 - $63.74 $10.6 Million - $12.3 Million	192,255 Added 62.25%	501,080 $31.9 Million
Q2 2017 Aug 09, 2017	BUY	N/A	308,825	308,825 $17.2 Million

Others Institutions Holding BMY

# of Institutions

2,428

Shares Held

1.5B

Call Options Held

29.7M

Put Options Held

32.2M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Calamos Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Calamos Advisors LLC with notifications on news.

Account

Calamos Advisors LLC Bristol Myers Squibb CO Transaction History